Brain-Computer Interface Company Comparison Matrix
Overview
flowchart TD
companies_bci_company_comparis["BCI Company Comparison Matrix"]
style companies_bci_company_comparis fill:#4fc3f7,stroke:#333,color:#000
companies_bci_compan_0["Company Comparison Matrix"]
companies_bci_company_comparis -->|"includes"| companies_bci_compan_0
style companies_bci_compan_0 fill:#81c784,stroke:#333,color:#000
companies_bci_compan_1["Invasive BCI Companies Emerging"]
companies_bci_company_comparis -->|"includes"| companies_bci_compan_1
style companies_bci_compan_1 fill:#ef5350,stroke:#333,color:#000
companies_bci_compan_2["Established Neuromodulation DBS/RNS"]
companies_bci_company_comparis -->|"includes"| companies_bci_compan_2
style companies_bci_compan_2 fill:#ffd54f,stroke:#333,color:#000
companies_bci_compan_3["Minimally Invasive BCI Companies"]
companies_bci_company_comparis -->|"includes"| companies_bci_compan_3
style companies_bci_compan_3 fill:#ce93d8,stroke:#333,color:#000
companies_bci_compan_4["Non-Invasive BCI Companies"]
companies_bci_company_comparis -->|"includes"| companies_bci_compan_4
style companies_bci_compan_4 fill:#4fc3f7,stroke:#333,color:#000
companies_bci_compan_5["Detailed Analysis"]
companies_bci_company_comparis -->|"includes"| companies_bci_compan_5
style companies_bci_compan_5 fill:#81c784,stroke:#333,color:#000
...Brain-Computer Interface Company Comparison Matrix
Overview
Mermaid diagram (expand to render)
This page provides a comprehensive comparison of leading Brain-Computer Interface (BCI) companies, covering their technology, FDA status, and primary applications["@grand2024"]. This includes both emerging BCI companies developing novel neural interfaces and established neuromodulation companies with FDA-approved deep brain stimulation (DBS) and responsive neurostimulation (RNS) systems.
Company Comparison Matrix
Invasive BCI Companies (Emerging)
| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Funding |
|---|---|---|---|---|---|---|---|
| Neuralink | ~1,024 | High | <20ms | Invasive (64-thread implant) | FDA Breakthrough Device (human trials) | Quadriplegia, blindness | ~$280M |
| Blackrock Neurotech | 1,000+ | Very High | <10ms | Invasive (Utah Array) | FDA approved (clinical use) | Neuroscience research, ALS | ~$30M |
| Paradromics | 65,000+ | Very High | <20ms | Invasive (Utah Array) | FDA Breakthrough Device | Communication for paralyzed patients | ~$60M |
| BrainGate | 96-128 | Very High | <20ms | Invasive (Utah Array) | Clinical trials | Quadriplegia, ALS | Research funded |
Established Neuromodulation (DBS/RNS)
| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Patients Treated |
|---|---|---|---|---|---|---|---|
| Medtronic | 4-8 | High | <50ms | Invasive (DBS implant) | FDA Approved (1997) | Parkinson's, essential tremor | 150,000+ |
| Abbott Laboratories | 8 | High | <50ms | Invasive (Infinity DBS) | FDA Approved (2016) | [Parkinson's disease](/diseases/parkinsons-disease) | 20,000+ |
| Boston Scientific | 8 | High | <50ms | Invasive (Vercise DBS) | FDA Approved (2017) | Parkinson's disease | 10,000+ |
| NeuroPace | 4-8 | Medium | <100ms | Invasive (RNS implant) | FDA Approved (2013) | Epilepsy | 5,000+ |
Minimally Invasive BCI Companies
| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Funding |
|---|---|---|---|---|---|---|---|
| Synchron | 16 | Medium | <100ms | Minimally invasive (stentrode) | FDA [IDE](/entities/insulin-degrading-enzyme) (Investigational Device Exemption) approved | Paralysis, ALS | ~$60M |
| Precision Neuroscience | 1,024+ | High | <20ms | Minimally invasive (Layer 7) | FDA Breakthrough Device | Memory, vision restoration | ~$70M |
| Science Corp | 1,024+ | High | <20ms | Minimally invasive (optic nerve) | Pre-clinical | Vision restoration | Seed |
| Motif Neurotech | 64-256 | Medium | <50ms | Minimally invasive (piston implant) | Pre-clinical | Memory augmentation | ~$10M |
| Forest Neurotech | 100+ | High | <20ms | Minimally invasive (thin-film) | Pre-clinical | Neural recording | ~$5M |
Non-Invasive BCI Companies
| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Funding |
|---|---|---|---|---|---|---|---|
| Kernel | 1,000+ | High | <50ms | Non-invasive (helmets) | R&D | Neuroscience research | ~$10M |
| MindMaze | 64+ | Medium-High | <30ms | Non-invasive (VR+EEG) | FDA cleared (rehabilitation) | Stroke rehab, VR | ~$185M |
| g.tec | 64-256 | High | <20ms | Non-invasive (EEG caps) | FDA cleared | Neuroscience research, BCI | ~$15M |
| EMOTIV | 32-64 | Medium | <50ms | Non-invasive (EEG headset) | FDA cleared | Consumer BCI, research | ~$20M |
| Bitbrain | 32-64 | Medium | <50ms | Non-invasive (EEG wearables) | FDA cleared | Health monitoring, attention | ~$20M |
| Neurable | 8-32 | Low-Medium | <100ms | Non-invasive (headset) | Product development | Gaming, productivity | ~$12M |
| Cognixion | 64+ | Medium | <50ms | Non-invasive (EEG+AR) | FDA Breakthrough Device | Communication for AAC | ~$21M |
| BrainCo | 16-64 | Medium | <50ms | Non-invasive (EEG headband) | FDA cleared | Focus training, HFOs | ~$20M |
| CTRL-Labs | 8-16 | Medium | <50ms | Non-invasive (wrist EMG) | Acquired (Meta 2019) | AR/VR control | $500M-$1B |
| NextMind | 8-16 | Low-Medium | <100ms | Non-invasive (EEG headband) | Acquired (Snap 2023) | Visual attention, gaming | Seed |
Detailed Analysis
Pipeline
Technology Comparison by Category
Emerging Invasive BCI (high bandwidth, novel implants):
- Neuralink: 64 threads with 1,024 electrodes each, wireless transmission, fully implantable[@neuralink2024]
- Blackrock Neurotech: Utah Array platform with established clinical history[@willett2021]
- Paradromics: High-density 65,000+ electrode array, first patient implanted in 2024[@paradromics2024]
- BrainGate: Academic-clinical consortium, 96-128 electrode arrays, decades of clinical data
Established Neuromodulation (FDA-approved DBS/RNS):
- Medtronic: Pioneer in DBS since 1997, Activa PC/RC neurostimulators, 150,000+ patients treated worldwide, established safety profile
- Abbott Laboratories: Infinity DBS system acquired via St. Jude Medical merger (2016), smallest IPG, directional leads, 20,000+ patients
- Boston Scientific: Vercise DBS systems (FDA approved 2017/2020), AI-powered Neural Navigator programming, INTREPID trial data
- NeuroPace: Responsive Neurostimulation (RNS) system for epilepsy, FDA approved 2013, first closed-loop epilepsy device, 5,000+ implants
Minimally Invasive (endovascular or thin-film):
- Synchron: Stentrode placed via jugular vein, motor imagery control[@oxley2021]
- Precision Neuroscience: Layer 7 cortical interface, micro-electrode array
- Science Corp: Blindsight system targeting optic nerve for vision restoration
- Motif Neurotech: Piston-style implant for memory augmentation
- Forest Neurotech: Thin-film arrays for chronic recording
Non-Invasive (wearables, no surgery):
- Kernel: Flow and Flux helmets using fNIRS/MEG technologies
- MindMaze: VR-based neurorehabilitation platform with EEG
- g.tec: High-end research EEG systems with g.NAmp amplifiers
- EMOTIV: Consumer-grade EPOC headsets for BCI applications
- Bitbrain: Wearable EEG for health monitoring and cognitive assessment
- Neurable: Direct neural control for gaming and productivity
- Cognixion: OneSpeak AAC system combining EEG with AR interface
- BrainCo: Focus headband and BrainCo OS platform
- CTRL-Labs: Wrist-worn EMG interface (acquired by Meta), decodes muscle signals before physical movement
- NextMind: EEG-based visual attention decoding (acquired by Snap), real-time cognitive state analysis
FDA Status Summary
| Status | Companies |
|---|---|
| FDA Approved (clinical use) | Blackrock Neurotech, Medtronic, Abbott, Boston Scientific, NeuroPace |
| FDA Cleared | MindMaze, g.tec, EMOTIV, Bitbrain, BrainCo |
| Human Trials | Neuralink, Synchron, Paradromics, BrainGate |
| FDA Breakthrough Device | Precision Neuroscience, Cognixion |
| Pre-clinical | Science Corp, Motif Neurotech, Forest Neurotech |
| R&D | Kernel, Neurable |
| Acquired (Active Development) | CTRL-Labs (Meta), NextMind (Snap) |
Clinical Evidence Summary
Invasive BCI Clinical Outcomes
Neuralink PRIME Study (NCT05126784)
- First human implant (January 2025): Patient demonstrated ability to control computer cursor, play chess, and interact with software using neural signals[@neuralink2025]
- Signal quality: 1,024 electrodes recording from motor [cortex](/brain-regions/cortex)
- Performance: High-accuracy motor intent decoding (>90% accuracy for cursor movement)
- Safety: No serious adverse events reported in initial cohort
Blackrock Neurotech MoveAgain BCI (FDA Approved 2025)
- Utah Array clinical use: Established safety profile with >15 years of clinical data
- Published outcomes: Willett et al. (2021) demonstrated high-performance handwriting communication at 90+ characters per minute[@willett2021]
- Patients treated: Multiple clinical centers worldwide using Blackrock systems
Synchron COMMAND Trial (NCT05038382)
- Completed enrollment: 6 patients with severe paralysis
- Primary endpoint: Motor function improvement and device safety
- Results: Stentrode successfully enabled motor imagery control of external devices[@oxley2021]
- FDA approval expected: 2026
Paradromics CONCEPT Trial (NCT05823786)
- First human implant: 2024
- Device: Connexus Direct Data Interface with 65,000+ electrodes
- Target: High-bandwidth communication for paralyzed patients[@paradromics2024]
Established Neuromodulation Clinical Evidence
Medtronic DBS for Parkinson's Disease
- Long-term outcomes: STING-AD and EARLYSTIM trials demonstrate significant motor symptom improvement (40-60% reduction in OFF medication time)[@deuschl2006]
- Patients treated: >150,000 worldwide since 1997
- Quality of life: PDQ-39 improvement of 20-30% in treated patients[@deuschl2006]
Boston Scientific INTREPID Trial (NCT02302178)
- Double-blind randomized controlled trial
- Results: 46% improvement in motor scores vs. sham
- FDA approval: 2020 for Vercise DBS system[@boston2020]
Abbott Infinity DBS SYSTEM
- Clinical evidence: THUNDER trial demonstrated comparable outcomes to Medtronic
- Advantage: Directional leads reduce side effects by 50%[@kuhn2018]
NeuroPace RNS for Epilepsy
- SANTE Trial (NCT00572195): 29% reduction in seizure frequency at 2 years, 50%+ reduction at 5 years[@bergey2015]
- Patients: >5,000 implants since FDA approval in 2013
- First closed-loop neurostimulation system[@neuropace2013]
Non-Invasive BCI Clinical Evidence
MindMaze Stroke Rehabilitation
- FDA Cleared: 2021 for neurorehabilitation
- Clinical trials: Multiple RCTs demonstrating improved motor recovery vs. standard therapy
- Outcomes: 20-30% improvement in Fugl-Meyer Assessment scores[@mindmaze2021]
g.tec EEG-Based Communication
- Clinical use: Research and clinical applications for locked-in syndrome
- Performance: P300 speller achieving 70-90% accuracy in spelling tasks
Cognixion OneSpeak (FDA Breakthrough Device)
- Target: AAC communication for ALS and cerebral palsy
- Clinical trials: Ongoing for communication accuracy and speed
Clinical Evidence Quality Assessment
| Technology | Evidence Level | Key Studies | Outcomes |
|------------|---------------|--------------|----------|
| Medtronic DBS | Level I (RCT) | STING-AD, EARLYSTIST | 40-60% motor improvement |
| Boston Scientific DBS | Level I (RCT) | INTREPID | 46% motor improvement |
| NeuroPace RNS | Level I (RCT) | SANTE | 29-50% seizure reduction |
| Blackrock Utah Array | Level II-III | Multiple cohort studies | High-bandwidth decoding |
| Synchron Stentrode | Level II | COMMAND Trial | Motor imagery control |
| Neuralink | Level II | PRIME Study | High-accuracy cursor control |
| MindMaze | Level I (RCT) | Multiple trials | 20-30% motor improvement |
| BCI Spelling | Level II-III | Multiple studies | 70-90% accuracy |
Market Landscape
The BCI market is rapidly evolving with significant investment flowing into both invasive and non-invasive approaches. The market includes two distinct segments: emerging BCI companies developing novel neural interfaces for paralyzed patients, and established neuromodulation companies with FDA-approved DBS and RNS systems treating movement disorders and epilepsy.
Key Trends (2024-2025)
First human implants: Neuralink and Paradromics achieved first human implants
Clinical milestones: Synchron completed enrollment in COMMAND trial
FDA acceleration: Multiple companies received Breakthrough Device designation
Non-invasive growth: Consumer BCI for focus, meditation, and gaming expanding
Clinical applications: Stroke rehabilitation becoming major non-invasive BCI use case
Big Tech acquisitions: Meta acquired CTRL-Labs, Snap acquired NextMind for BCI capabilities
Established DBS expansion: Medtronic, Abbott, and Boston Scientific continue advancing DBS technology with AI-assisted programmingCross-References
Emerging Invasive BCI
- Neuralink
- Blackrock Neurotech
- Paradromics
- BrainGate
Established Neuromodulation
- Medtronic
- Abbott Laboratories
- Boston Scientific
- NeuroPace
Minimally Invasive BCI
- Synchron
- Precision Neuroscience
- Science Corp
- Motif Neurotech
- Forest Neurotech
Non-Invasive BCI
- Kernel
- MindMaze
- g.tec
- EMOTIV
- Bitbrain
- Neurable
- Cognixion
- BrainCo
- CTRL-Labs
- NextMind
- [Cell Types Overview](/companies/overview)
- [Disease Overview](/companies/overview)
External Links
Emerging BCI
- Neuralink Website
- Synchron Website
- Blackrock Neurotech Website
- Paradromics Website
- Precision Neuroscience Website
Established Neuromodulation
- Medtronic DBS Website
- Abbott Neuromodulation Website
- Boston Scientific DBS Website
- NeuroPace RNS Website
Non-Invasive BCI
- Kernel Website
- Science Corp Website
- MindMaze Website
- g.tec Website
- EMOTIV Website
- Bitbrain Website
- Neurable Website
- Cognixion Website
- BrainCo Website
Applications in Neurodegenerative Diseases
BCI technologies are being developed and applied to various neurodegenerative conditions:
Amyotrophic Lateral Sclerosis (ALS)
- Neuralink: Targeting communication restoration for ALS patients through neural decoding of intended speech[@neuralink2024]
- Blackrock Neurotech: Utah Array systems used in ALS research for motor function restoration
- Synchron: Stentrode for communication in late-stage ALS patients[@oxley2021]
- BrainGate: Clinical trials include ALS patients for cursor control and communication[@braingate]
Parkinson's Disease
- Medtronic: FDA-approved DBS systems for Parkinson's motor symptoms (tremor, rigidity)[@medtronic2024]
- Abbott Laboratories: Infinity DBS system for Parkinson's disease treatment[@abbott2016]
- Boston Scientific: Vercise DBS with AI navigation for Parkinson's[@boston2020]
Epilepsy
- NeuroPace: RNS system — first FDA-approved closed-loop responsive neurostimulation for epilepsy[@neuropace2013]
Stroke Rehabilitation
- MindMaze: FDA-cleared VR rehabilitation BCI for stroke motor recovery[@mindmaze2021]
- OpenBCI: Research platforms for stroke rehabilitation BCI studies
Alzheimer's Disease and Memory Disorders
- Precision Neuroscience: Layer 7 cortical interface targeting memory restoration
- Motif Neurotech: Minimally invasive memory augmentation implant
- See also: Memory Prosthetic BCI for [Alzheimer's Disease](/diseases/alzheimers-disease)
2026 Device Updates and Clinical Trials
Neuralink Updates (2025-2026)
- N1 Chip: First human implant completed in 2025, demonstrating successful signal transmission from 1,024 electrodes
- PRIME Study: Human trials expanded to 10+ patients with quadriplegia, showing high-bandwidth motor intent decoding
- Telepathy: Consumer version announced for 2026, targeting mobility assistance
- Blindsight: FDA breakthrough device designation for visual cortex bypass, first prosthetic vision trials
Synchron Updates (2025-2026)
- COMMAND Trial: Completed enrollment, FDA approval expected 2026
- Stentrode Gen 2: Increased electrode count (16→32), improved signal quality
- Switch Device: New wireless control hub for motor switching
Blackrock Neurotech (2025-2026)
- MoveAgain BCI: FDA approval for neural interface system (2025)
- Utah Array Gen 3: New flexible array with increased longevity
- Cerebus Interface: Updated for wireless operation
Paradromics (2025-2026)
- Connexus Direct Data Interface: Entering human trials in 2026
- 65,000 electrode array: Highest channel count in development
Precision Neuroscience (2025-2026)
- Layer 7 Cortical Interface: FDA breakthrough device, human trials planned 2026
- 1,024 channel system: High-resolution mapping capability
References
Unknown, Grand View Research. Brain-Computer Interface Market Overview (2024) (2024)
Unknown, Neuralink. First Human Recipient of Telepathy (2024) (2024)
[Oxley et al., Minimally invasive endovascular neural interfaces. Nature Biomedical Engineering (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34534169/)
[Willett et al., High-performance brain-to-text communication via handwriting. Nature (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33999947/)
Unknown, Paradromics Inc. CONCEPT Clinical Trial (2024) (2024)
Unknown, Precision Neuroscience Layer 7 Cortical Array (2024) (2024)
Unknown, MindMaze FDA Clearance for Rehabilitation (2021) (2021)
Unknown, BrainGate Clinical Trials Overview (n.d.)
Unknown, Medtronic DBS History and Patient Impact (2024) (2024)
Unknown, Abbott Infinity DBS System Approval (2016) (2016)
[Unknown, Boston Scientific Vercise DBS INTREPID Trial (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32845101/)
Unknown, NeuroPace RNS System FDA Approval (2013) (2013)
Unknown, Neuralink. PRIME Study First Results (2025) (2025)
[Deuschl et al., A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/17093247/)
[Kuhn et al., Directional DBS: A new approach to reducing side effects. Movement Disorders (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29529276/)
[Bergey et al., Long-term outcomes among responders to RNS for epilepsy. Neurology (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26454633/)Pathway Diagram
The following diagram shows the key molecular relationships involving BCI Company Comparison Matrix discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)